TAPP Submits Comments to Centers for Medicare & Medicaid Services, Advocates for Medical Innovators

TAPP submitted comments to the Centers for Medicare & Medicaid Services to oppose a proposed rule change regarding prescription drugs. Particularly, the rule change that would result in an annual survey, conducted by the federal government, on American life science companies.

The survey is supposed to be about price verification for prescription drugs, but in reality it would be an audit of private American companies performed by the federal government. The proposed rule change would place unnecessary burdens on American medical innovators and would hinder the production of lifesaving medicines.

Government mandates on life science companies are bad for everyone involved. This would result in fewer cures for patients, fewer choices for doctors, and fewer dollars invested into the American economy.

The proposed rule change for price verification surveys must be opposed.

View TAPP’s comments here.